AUS
NZ
UK
CA
USA
IND
_06_16_2026_06_12_08_773360.jpg)
Source: Aedka Studio, Shutterstock
Summary
- AstraZeneca has recently faced suspensions from several countries and now is awaiting the EU medical watchdog’s official verdict.
- The company’s shares are still in the green as the World Health Organization has cleared the vaccines for use.
British-Swedish drug maker AstraZeneca (LON: AZN) has recently faced suspensions from several countries following claims that its Covid-19 vaccine is causing blood clots, with France, Germany and Italy becoming the latest to suspend their vaccines.
EU leading medical regulator European Medicine Agency (EMA) is expected to announce its official verdict on Thursday on the risks associated with the vaccine.
On 15 March, the EMA had said that vaccine’s benefits outweigh its side effects. AstraZeneca’s shares were still trading higher as the World Health Organisation said it was suitable for mass inoculation.
The company’s stock price was at GBX 7,209.00, up by 3.31 per cent as of 16 March at 12:32 PM GMT+1, while the FTSE 100, which it is a part of, was at 6,799.09, up by 0.73 per cent. The company’s market capitalisation stood at £94.647 billion, while its 1-year return was at 14.15 per cent, and its 12-month trailing price-to-earnings ratio was at 29.60.
Here in this article, we take a closer look at two other high performing large cap global vaccine stocks:
- Novovax
US-based vaccine development company Novovax (NASDAQ:NVAX) on Monday announced that its vaccine was 96.4 per cent effective against the original strain in its Phase 3 study. It also reported a 55.4 per cent efficacy against the South African variant on HIV negative participants and 86.3 per cent efficacy against the UK variant.
Novovax’s (NASDAQ:NVAX) shares were trading at USD 219.01, up by 0.71 per cent on 16 March at 09:31 AM GMT-4, while the broader index, Nasdaq Composite, stood at 13,520.22, up by 0.45 per cent for the same period. The company’s market cap stood at US $16.061 billion.
Also Read: 4 Aspects That Can Decide The Future Of Vaccines
Copyright © 2021 Kalkine Media Pty Ltd.
- Moderna
US-based pharmaceutical giant Moderna (NASDAQ:MRNA) announced it had started administering its vaccine mRNA-1273 to children aged between six months and less than 12 years in the US and Canada, on Tuesday. The study aims to assess the efficacy and safety of the vaccine in this age group and plans to enrol up to 6,750 participants.
The company is also testing the vaccine on children aged between 12 to 18 years of age in a separate study.
Moderna’s (NASDAQ:MRNA) shares stood at USD 148.70, up by 3.51 per cent on 16 March at 09:31 AM GMT-4 following the news. The company’s market cap stood at US $57.539 billion.
Also Read: Will Moderna’s booster shots be effective on South African variant?
